AQST vs EOLS: stock comparison and AI forecast
Aquestive Therapeutics, Inc. (AQST) and Evolus, Inc. (EOLS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
AQST Aquestive Therapeutics, Inc.
- Price
- $3.61 -16.8% · 6M
- Market Cap
- $453M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
EOLS Evolus, Inc.
- Price
- $6.80 +7.7% · 6M
- Market Cap
- $449M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- AQST and EOLS have similar market capitalizations ($453M and $449M).
- Over the last six months EOLS returned +7.7% and AQST -16.8%.
- EOLS turns -9.6% of its revenue into net income, against -162.3% for AQST.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | AQST | EOLS |
|---|---|---|
| Market Cap | $453M | $449M |
| EPS | $-0.77 | $-0.75 |
| Revenue/Share | $0.39 | $4.93 |
| FCF/Share | $-0.32 | $-0.07 |
Profitability & Margins
| Metric | AQST | EOLS |
|---|---|---|
| ROA | -66.4% | -11.0% |
| ROIC | -54.6% | -11.0% |
| Gross Margin | 65.3% | 66.4% |
| Operating Margin | -114.1% | -4.8% |
| Net Margin | -162.3% | -9.6% |
| EBT Margin | -162.3% | -9.3% |
| Tax Rate | 0.0% | -2.5% |
Financial Health
| Metric | AQST | EOLS |
|---|---|---|
| Current Ratio | 6.12x | 1.42x |
| Quick Ratio | 5.69x | 0.84x |
| Interest Coverage | -3.9x | -1.2x |
| Working Capital | $89M | $59M |
Cash Flow
| Metric | AQST | EOLS |
|---|---|---|
| Operating Cash Flow | -$40M | -$3M |
| Free Cash Flow | -$41M | -$5M |
| Capital Spending | -$930K | -$2M |
| FCF/Sales | -83.3% | -1.5% |
| CapEx/Sales | 1.9% | 0.7% |
Operational Efficiency
| Metric | AQST | EOLS |
|---|---|---|
| Asset Turnover | 0.41x | 1.15x |
| Receivables Turnover | 9.3x | 5.4x |
| Inventory Turnover | 2.3x | 1.3x |
| Fixed Assets Turnover | 11.2x | 67.1x |
| Days Sales Outstanding | 39 days | 68 days |
| Days Inventory | 158 days | 276 days |
| Payables Period | 190 days | 288 days |
| Cash Conversion Cycle | 7 days | 56 days |
Income Statement
| Metric | AQST | EOLS |
|---|---|---|
| Total Revenue | $49M | $325M |
| Operating Income | -$56M | -$16M |
| Net Income | -$79M | -$31M |
| R&D Expense | $16M | $10M |
| SG&A Expense | $72M | $217M |
| Cost of Goods Sold | $17M | $109M |
Dividend & Shareholder Information
| Metric | AQST | EOLS |
|---|---|---|
| Shares Outstanding | 126M | 66M |
AQST vs EOLS: stock comparison and AI forecast
Which is bigger, AQST or EOLS?
AQST and EOLS have similar market capitalizations ($453M and $449M).
Which stock performed better over the last six months, AQST or EOLS?
Over the last six months EOLS returned +7.7% and AQST -16.8%.
Which one does Intratio's AI model rank higher, AQST or EOLS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.